Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $56.36

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has received an average recommendation of “Moderate Buy” from the fifteen research firms that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $56.36.

KYMR has been the subject of a number of recent research reports. BMO Capital Markets started coverage on Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 target price for the company. BTIG Research initiated coverage on Kymera Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective for the company. Leerink Partners reissued an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Citigroup started coverage on shares of Kymera Therapeutics in a report on Thursday. They issued a “buy” rating and a $52.00 target price on the stock. Finally, Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $38.00 to $57.00 in a report on Monday, December 2nd.

Insider Buying and Selling at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares of the company’s stock, valued at $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ellen Chiniara sold 3,129 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the transaction, the insider now owns 54,826 shares in the company, valued at approximately $2,288,985.50. This represents a 5.40 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,788 shares of company stock worth $455,202. Insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Blue Trust Inc. boosted its stake in Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after acquiring an additional 270 shares during the last quarter. State of Wyoming acquired a new position in shares of Kymera Therapeutics in the 4th quarter valued at $45,000. GF Fund Management CO. LTD. bought a new position in shares of Kymera Therapeutics in the 4th quarter worth $55,000. KBC Group NV grew its stake in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares during the period. Finally, Quarry LP bought a new stake in Kymera Therapeutics in the third quarter valued at about $95,000.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $34.37 on Friday. Kymera Therapeutics has a 52-week low of $29.07 and a 52-week high of $53.27. The firm has a market capitalization of $2.23 billion, a PE ratio of -14.69 and a beta of 2.22. The company’s fifty day moving average price is $37.43 and its two-hundred day moving average price is $42.76.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $7.39 million during the quarter, compared to the consensus estimate of $14.81 million. Analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.